Skip to main content
PELL BMT logo

PELL BMT — Investor Relations & Filings

Ticker · 6949 ISIN · TW0006949001 TW Professional, scientific and technical activities
Open in API
Filings indexed 18 across all filing types
Latest filing 2026-04-08 Director's Dealing
Country TW Taiwan
Listing TW 6949

About PELL BMT

https://www.pellbmt.com

Pell Biologics & Medical Technology Co., Ltd. specializes in the research, development, and clinical application of advanced cell and gene therapies. The company’s core expertise lies in Chimeric Antigen Receptor T-cell (CAR-T) therapy, adoptive T-cell therapy, and stem cell-based regenerative medicine. Its primary R&D pipeline includes CD19 CAR-T treatments for B-cell lymphoma, alongside Cytokine-Induced Killer (CIK) and Dendritic Cell-Cytokine Induced Killer (DC-CIK) immunotherapies. In the field of regenerative medicine, the company develops adipose-derived stem cell (ADSC) applications for degenerative arthritis and tissue repair. Operating within GTP and GMP-compliant facilities, the company focuses on critical technologies for cell isolation, activation, and expansion to deliver personalized precision medicine and high-quality cellular products.

Recent filings

Filing Released Lang Actions
115年03月內部人持股異動(事後)
Director's Dealing Classification · 89% confidence The document is a regulatory disclosure from the Taiwanese public information site showing detailed insider holdings and month-to-month changes for directors, chairperson, senior management, and their related parties. It lists ‘本月增加’ and ‘本月減少’ for each internal person’s share transactions. This matches the definition of a Director’s Dealing report (insider share transactions by company directors and executives).
2026-04-08 Chinese
115年03月董事會成員及持股
Director's Dealing Classification · 91% confidence The document is a regulatory disclosure from Taiwan’s MOPS showing shareholdings and pledged shares of corporate insiders (directors, management) at appointment and current levels, including spouse/child holdings. This matches an insider shareholding/trading report. Under our taxonomy, such items fall under Director's Dealing (DIRS).
2026-04-08 Chinese
代100%持有之子公司沛(月太)(上海)醫藥科技有限公司公告， 本公司研發針對類風濕關節炎(RA)之口服新藥PP011，向中國 國家藥品監督管理局(NMPA)遞交第一期臨床試驗許可申請(IND)
Regulatory Filings Classification · 95% confidence The document is a Taipei Exchange/TPEx material event disclosure (“重大訊息”) from a listed biotech company reporting that its subsidiary has submitted an IND application for a Phase I clinical trial in China. It is not an earnings release, annual or interim report, nor a proxy or dividend announcement; rather it is a routine regulatory filing of a corporate material event that does not fit other specific categories. Thus, it falls under the generic Regulatory Filings category (RNS).
2026-03-30 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.